Scott Nicholas Gettinger, MD

Associate Professor of Medicine (Medical Oncology)

Clinical Interests

  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Internal Medicine: Medical Oncology: Subset Medical Oncology Faculty

Cancer Center, Yale: Thoracic Oncology Program

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Hematology (Internal Medicine)

Clinical Trials

Conditions Study Title
Lung Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer
Lung A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Cou
Lung A081105: Erlotinib Hydrochloride in Patients w/Stage IB-IIIA NSCLC That Has Been Removed Surgically
Lung E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been R
Lung A151216:Genetic Testing in Screening Patients w/Stage IB-IIIA NSCLC That Has Been or Will Be Removed
Lung Phase 3 study MPDL3290A with Cisplatin or Carboplatin+Pemetrexed for PD-L1- Stage 4 NSCLC
Lung Phase 3, MPDL3280A with Carboplatin+Paclitaxel or Carboplatin+Paclitaxel+Bevacizumab in NSCLC
Brain and Nervous System, Lung, Melanoma, skin Pembrolizumab and bevacizumab in untreated brain metastases
Lung Phase 3 - Nivo, or Nivo+Ipilmumab vs. platinum doublet chemo in chemotherapy-naive stage 4 or NSCLC
Lung Study Of PF-06463922 An ALK/ROS1 Inhibitor In Advanced NSCLC w/Specific Molecular Alterations
Lung Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent NSCLC
Lung CheckMate 331: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 331
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Lung A randomized phase II trial of combination versus single agent chemotherapy in high-risk elderly pat
Lung Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Lung S1403
Lung PINNACLE: Phase 1b/2 Study of Anti-Notch Antibody Therapy with Cisplatin and Etoposide in SCLC
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Lung, Phase I A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB o
Lung Safety and Efficacy of Abraxane Maintenance post Abraxane + Carboplatin in squamous cell lung cancer

Edit this profile

Contact Info

Scott Nicholas Gettinger, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208028
New Haven, CT 06520-8028